Clinical Trial Update: Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial testing EBV-specific cytotoxic T cells in relapsed EBV-positive lymphomas has completed, assessing safety and preliminary activity across several …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Active Ebv Infection
• Hodgkin Lymphoma
• Leiomyosarcoma
• Nasopharyngeal Carcinoma
• Non-hodgkin Lymphoma

Drugs mentioned

• EBV-specific cytotoxic T lymphocytes (EBV-specific cytotoxic T lymphocytes)

Snippet

Sponsor: Catherine Bollard | Conditions: Hodgkin Disease, Non Hodgkin Lymphoma | Phase 1 | Status: COMPLETED